Cargando…
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis
BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626283/ https://www.ncbi.nlm.nih.gov/pubmed/28953640 http://dx.doi.org/10.1097/MD.0000000000008120 |
_version_ | 1783268519847133184 |
---|---|
author | Li, Mei-Juan Li, Qing Sun, Min Liu, Li-Qin |
author_facet | Li, Mei-Juan Li, Qing Sun, Min Liu, Li-Qin |
author_sort | Li, Mei-Juan |
collection | PubMed |
description | BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24–1.71)] and 8 weeks [1.58 (1.29–1.92)], and improved the heartburn relief rates [1.29 (1.07–1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10–1.53)] and 8 weeks [1.37 (1.13–1.67)], and improved the heartburn relief rates [1.29 (1.03–1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03–2.29)], pantoprazole 40 mg [1.68 (1.08–2.63)], and lansoprazole 30 mg [1.38 (1.02–1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions. |
format | Online Article Text |
id | pubmed-5626283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-56262832017-10-11 Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis Li, Mei-Juan Li, Qing Sun, Min Liu, Li-Qin Medicine (Baltimore) 4500 BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24–1.71)] and 8 weeks [1.58 (1.29–1.92)], and improved the heartburn relief rates [1.29 (1.07–1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10–1.53)] and 8 weeks [1.37 (1.13–1.67)], and improved the heartburn relief rates [1.29 (1.03–1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03–2.29)], pantoprazole 40 mg [1.68 (1.08–2.63)], and lansoprazole 30 mg [1.38 (1.02–1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions. Wolters Kluwer Health 2017-09-29 /pmc/articles/PMC5626283/ /pubmed/28953640 http://dx.doi.org/10.1097/MD.0000000000008120 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 |
spellingShingle | 4500 Li, Mei-Juan Li, Qing Sun, Min Liu, Li-Qin Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title_full | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title_fullStr | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title_full_unstemmed | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title_short | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
title_sort | comparative effectiveness and acceptability of the fda-licensed proton pump inhibitors for erosive esophagitis: a prisma-compliant network meta-analysis |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626283/ https://www.ncbi.nlm.nih.gov/pubmed/28953640 http://dx.doi.org/10.1097/MD.0000000000008120 |
work_keys_str_mv | AT limeijuan comparativeeffectivenessandacceptabilityofthefdalicensedprotonpumpinhibitorsforerosiveesophagitisaprismacompliantnetworkmetaanalysis AT liqing comparativeeffectivenessandacceptabilityofthefdalicensedprotonpumpinhibitorsforerosiveesophagitisaprismacompliantnetworkmetaanalysis AT sunmin comparativeeffectivenessandacceptabilityofthefdalicensedprotonpumpinhibitorsforerosiveesophagitisaprismacompliantnetworkmetaanalysis AT liuliqin comparativeeffectivenessandacceptabilityofthefdalicensedprotonpumpinhibitorsforerosiveesophagitisaprismacompliantnetworkmetaanalysis |